

May 11, 2017

Company Name: ONO PHARMACEUTICAL CO., LTD.  
 Representative: Gyo Sagara, President and Representative Director  
 Securities Code: 4528, First Section of the Tokyo Stock Exchange  
 Inquiries: Yukio Tani, Director, Corporate Communications  
[public\\_relations@ono.co.jp](mailto:public_relations@ono.co.jp)

## Notice regarding Differences between Non-consolidated Results for the Fiscal year Ended March 31, 2017 and those for the Previous Fiscal Year

ONO PHARMACEUTICAL CO., LTD. (Osaka, Japan; President and Representative Director, Gyo Sagara; “ONO”) announced today that there were been differences between its non-consolidated results (Japanese standard) for the fiscal year ended March 2017 (April 1, 2016 to March 31, 2017) and those for the previous fiscal year.

### Details

1. Differences between the full-year non-consolidated results for the fiscal year ended March 2017 (April 1, 2016 – March 31, 2017) and those for the previous fiscal year

(Unit: Millions of yen, except basic earnings per share)

	Net Sales	Operating Profit	Profit before Tax	Profit (Owners of the Parent Company)	Basic Earnings per Share (yen)
Previous Results (A) (FY ended March 2016)	159,356	22,657	24,460	20,775	39.19
Revised Results (B) (FY ended March 2017)	243,265	47,107	47,787	51,535	97.22
Change (B – A)	83,908	24,450	23,327	30,760	-
Change (%)	52.7	107.9	95.4	148.1	-

(Note) The company conducted a stock split of common stocks at a ratio of 1:5 with an effective date of April 1, 2016. As for “Basic earnings per share”, it is calculated assuming that the stock split was conducted at the beginning of the previous period.

### 2. Reasons for the revision

Because growth in sales of Opdivo Intravenous Infusion contributed to higher net sales, there were differences between the full-year non-consolidated results for the fiscal year ended March 31, 2017 and those for the previous fiscal year.